Abstract

This study evaluated the feasibility of utilizing a 3D-printed anthropomorphic patient-specific head phantom for patient-specific quality assurance (QA) in intensity-modulated radiotherapy (IMRT). Contoured left and right head phantoms were converted from DICOM to STL format. Fused deposition modeling (FDM) was used to construct an anthropomorphic patient-specific head phantom with a 3D printer. An established QA technique and the patient-specific head phantom were used to compare the calculated and measured doses. When the established technique was used to compare the calculated and measured doses, the gamma passing rate for γ ≤ 1 was 97.28%, while the gamma failure rate for γ > 1 was 2.72%. When the 3D-printed patient-specific head phantom was used, the gamma passing rate for γ ≤ 1 was 95.97%, and the gamma failure rate for γ > 1 was 4.03%. The 3D printed patient-specific head phantom was concluded to be highly feasible for patient-specific QA prior to complicated radiotherapy procedures such as IMRT.

Highlights

  • The effectiveness of radiotherapy is maximized by delivering the highest possible dose of radiation to a tumor while minimizing the effect on normal tissues [1,2]

  • The dose distribution needs to be calculated with a radiation treatment planning system (RTPS), and patient-specific quality assurance (QA) is needed to validate the dose distribution

  • The computed tomography (CT) image used in this study was a Digital Imaging and Communications in Medicine (DICOM) file intended for use in the radiotherapy treatment plan for head and neck cancer patients

Read more

Summary

Introduction

The effectiveness of radiotherapy is maximized by delivering the highest possible dose of radiation to a tumor while minimizing the effect on normal tissues [1,2]. The dose distribution needs to be calculated with a radiation treatment planning system (RTPS), and patient-specific quality assurance (QA) is needed to validate the dose distribution. Dose distributions can be measured by either using a chamber (i.e., point dosimetry) or a film or diode array detector (i.e., two-dimensional dosimetry) [4,5]. For patient-specific QA using a film or array detector, the gamma index is currently used extensively to validate the difference between the calculated and measured doses [6,7].

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.